Investor Deck – Q4 FY26 May 12, 2026 Certain statements in this release concerning Sagility’s future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. Sagility does not undertake to update any such statement that may have been made from time to time by or on behalf of the company. Safe Harbor Performance Highlights FY26 Revenue Adjusted EBITDA Adjusted PAT ₹ 20,243 Million ₹ 5,036 Million ₹ 3,069 Million YoY growth 29.1% 22.2% in CC Margin % 24.9% Margin % 15.2% YoY Growth (Excl. Broadpath) 25.8% YoY growth % 20.6% YoY growth % 28.0% Revenue Adjusted EBITDA Adjusted PAT ₹ 71,929 Million ₹ 18,200 Million ₹ 11,306 million YoY growth 29.1% 23.6% in CC Margin % 25.3% Margin % 15.7% YoY Growth (Excl. Broadpath) 20.1% YoY growth % 23.9% YoY growth % 39.5% Q4 FY26 ▶ 25.8% Y-o-Y organic growth in FY26, driven by expansion within existing clients and rising contribution from FY26 new client wins ▶ $30.7M (potential steady state ACV) of new business & expansion won in Q4 FY26 ▶ Expansion and new SOWs from 18 existing clients and 2 FY26 new logos in Q4 FY26 ▶ 5 new clients onboarded in Q4 (total 17 in FY26) ▶ Sagility is advancing AI orchestration through SmarTec and Synchrony to drive smarter, end-to-end operations and measurable outcomes ▶ Sagility’s brand evolution positions it as a Tech & AI-led operations partner focused on delivering measurable outcomes Insights • Leader Healthcare Payer Agility and Innovation 2026 NEAT NelsonHall • Leader Healthcare Payer Intelligent Operations PEAK Matrix® Assessment 2026 Everest • Leader in Generative AI services by ISG • Sagility SmarTec Nurse Assist was the Winner of Augmented Intelligence award by Business Intelligence Group Rewards & Recognitions 19.4% in CC 15.0% in CC Final dividend of ₹0.1 per share KPIs Note: *Adjusted EBITDA represents EBITDA adjustedfor earnouts payable under acquisition agreements (DCI,BirchAI&BroadPath), share-based payment awards and exclude other income (including forex gain/loss). *Adjusted PAT reflects EBITDA adjustments and adjustments for amortisation of intangible assets arising from the carve-out of the healthcare business from HGS, as well as the statutory impact of the new labor codes in India, net of tax ^Voluntary attrition is calculated for employees with tenure exceeding 90 days and presented on an annualized basis, derived from voluntary exits during the respective quarter Q4 FY26 Q3 FY26 Q4 FY25 YoY% FY26 FY25 YoY% Revenue from Operation (in ₹M) 20,243 19,712 15,685 29.1% 71,929 55,699 29.1% Revenue by Vertical Split By Payer % 90.8% 90.4% 89.7% 89.7% 89.4% By Provider % 9.2% 9.6% 10.3% 10.3% 10.6% Growth in revenue from operation (%) 29.1% 35.7% 22.2% 29.1% 17.2% Adjusted EBITDA (in ₹M)* 5,036 5,125 4,176 20.6% 18,200 14,685 23.9% Adjusted EBITDA % 24.9% 26.0% 26.6% 25.3% 26.4% Adjusted PAT (in ₹M)** 3,069 3,229 2,398 28.0% 11,306 8,107 39.5% Adjusted PAT % 15.2% 16.4% 15.3% 15.7% 14.6% Total Number of Employees 46,860 48,522 39,409 18.9% 46,860 39,409 18.9% Voluntary attrition rate^ (%) 38.1% 22.8% 32.5% 29.4% 27.5% Annual KPIs FY26 FY25 FY24 FY23 Numbers of Client group Active 82 75 44 35 Number of new client addition (Gross) 17 38 13 7 Delivery Sites Number of delivery sites 31 33 30 27 New site addition (Gross) 4 10 4 2 Client groups contribution to revenues* Top 3 client % 59.9% 66.2% 68.3% 72.4% Top 5 client % 70.4% 77.9% 79.2% 80.6% Top 10 client % 83.9% 90.5% 91.4% 90.7% Number of Million-dollar client groups** Number of clients contributing more than US$20 million 9 7 5 4 Number of clients contributing to US$5 - US$20 million 7 6 7 7 Number of clients contributing to US$1 - US$5 million 21 12 12 12 Number of clients contributing less than US$1 million 45 50 20 12 **Client groups comprise client entities together with their affiliates. *Client group represent top client based on last twelve months revenue for the respective period Top 3 client CAGR of 9.1% (in CC) over FY23 to FY26. Overall CAGR of 16.2% ( in CC) over FY23 to FY26. Business Updates Recent Market Trends – Q4 Market Trends Impact on Payer Implications for Sagility CMS finalized Medicare Advantage Rates at 2.48% Y-o-Y increase This presents payers with a little more favorable reimbursement environment vs the near-flat proposal initially expected that eases some pressure on margins. Profitability pressures still continue though. Proposals that focus on cost takeout in administrative functions and improving STARs ratings resonate with payers who are still encountering increased medical utilization. House Passes Bill to extend/enhance ACA premium subsidies With coverage remaining affordable, Marketplace enrollment is expected to stay stable, supporting a favorable insured member risk mix heading into 2027 Payers are likely to sustain operational spend across enrollment, billing, and engagement services. While Sagility currently has low exposure to the ACA market, this strengthens the case for automation & AI led models to manage service complexity and cost pressures. State Medicaid expansion incentives have ended, effective 2026 The expiration of federal Medicaid expansion incentives removes a key catalyst for incremental state-level expansion activity, likely moderating future Medicaid membership growth. While Sagility has low exposure to the Medicaid market, cost optimization is likely to become a greater strategic priority for these plans, further accelerating adoption of automation-led operating models and efficiency-focused outsourcing initiatives. CMS launched the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model CMS’ push to outcome based chronic care management with tech-enabled care central to the model While this is focused on Original Medicare, it aligns closely with our strategic focus on helping MA plans with analytics-led care management, and technology-enabled member engagement and support services. Brand Promise Sagility delivers value in healthcare operations with deep domain expertise, technology & AI-led transformation, and trusted collaboration. 80+ Healthcare Clients 18 Average Client Tenure in Years 37 AI Use-Cases Deployed 4400+ Clinicians and Technology Experts 25+ Years exclusively in healthcare >50 NPS/CSAT Client Endorsed Solutioning 80 Executive Client Attendees Co-creating outcome-driven healthcare solutions with our clients - combining their operational insight with Sagility’s innovation to accelerate measurable impact. Innovation Forum Reducing Medical Costs – Clinical Context to Action Solution #1 Member Pain Index Reducing Payer/Provider Friction #2 #3 Key Client Themes • AI is rapidly reshaping operating models to lower medical costs while improving member and patient outcomes. • AI deployment decisions are becoming increasing collaborative with business operations and technology leaders jointly shaping the path forward. • The key to execution is through a robust partnership ecosystem resulting in outcomes-based decisioning versus traditional models. Financial Highlights Financial Highlights Revenue Adjusted EBITDA Adjusted PAT OCF ₹ 20,243 million ₹ 5,036 Million ₹ 3,069 Million ₹ 5,327 Million YoY growth 29.1% 22.2% at Constant Currency Margin % 24.9% Margin % 15.2% Conversion % 104.6% YoY Growth (Excl. Broadpath) 25.8% 19.4% at Constant Currency YoY growth % 20.6% YoY growth % 28.0% DSO 87 days Q4 FY26 FY26 FY26 marked by strong top-line growth, margin resilience, and healthy operating cash flow Revenue Adjusted EBITDA Adjusted PAT OCF ₹ 71,929 million ₹ 18,200 Million ₹ 11,306 Million ₹ 12,030 million YoY growth 29.1% 23.6% at Constant Currency Margin % 25.3% Margin % 15.7% Conversion % 64.7% YoY Growth (Excl. Broadpath) 20.1% 15.0% at Constant Currency YoY growth % 23.9% YoY growth % 39.5% DSO 87 days Quarterly Seasonality 12 35.4 35.9 38.4 39.6 39.4 39.9 44.2 Headcount (‘000) 48.5 39.4 46.9 Q4FY24 to Q4FY25 Q4FY25 to Q4FY26 Headcount (‘000) Revenue ($M) $154.4 $146.6 $157.9 $172.0 $181.8 Revenue ($M) $181.8 $180.4 $189.4 $222.0 $222.1 Our Revenues exhibit seasonality. Growth in Q3 & Q4 is impacted by Open Enrollment volumes 15,685 15,389 16,585 19,712 20,243 26.6% 24.0% 26.2% 26.0% 24.9% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 22,000 24,000 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Revenue ₹M Adjusted EBITDA % 12,832 12,233 13,250 14,531 15,685 24.5% 23.8% 26.1% 28.4% 26.6% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% 3,000 5,000 7,000 9,000 11,000 13,000 15,000 17,000 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Revenue ₹M Adjusted EBITDA % Includes 2 month of acquisition ($8.9M) Includes 2 month of acquisition ($8.9M) Long Term Financial performance snapshot 13 Revenue (₹M) FY25 YoY% FY26 YoY% 17.2% 29.1% Adjusted EBITDA * (₹M) FY25 YoY% FY26 YoY% 28.4% 23.9% Adjusted PAT (₹M) FY25 YoY% FY26 YoY% 37.5% 39.5% Revenue ($M) FY25 YoY% FY26 YoY% 14.9% 23.6% Adjusted EBITDA* ($M) FY25 YoY% FY26 YoY% 25.9% 18.7% Adjusted PAT ($M) FY25 YoY% FY26 YoY% 34.8% 33.5% *Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). Improved adjusted PAT driven by declining finance costs and higher forex gains ₹42,184 ₹47,536 ₹55,699 ₹71,929 FY23 FY24 FY25 FY26 $518.2 $572.9 $658.3 $814.0 FY23 FY24 FY25 FY26 ₹10,272 ₹11,436 ₹14,685 ₹18,200 FY23 FY24 FY25 FY26 ₹4,556 ₹5,896 ₹8,107 ₹11,306 FY23 FY24 FY25 FY26 $126.2 $137.8 $173.6 $206.0 FY23 FY24 FY25 FY26 $56.0 $71.1 $95.8 $127.9 FY23 FY24 FY25 FY26 Other Financial Indicators Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares 14 Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities) Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent including investment in Mutual Fund and Deposits . Borrowing doesn’t include accrued interest OCF conversion in FY26 @ 64.7% driven by higher Non-cash (unrealized) forex Gains, lower non-cash expenses and higher tax payouts 1.06 1.38 1.76 2.42 FY23 FY24 FY25 FY26 Adjusted EPS (in ₹) 41.6% 47.0% 54.9% 57.4% FY23 FY24 FY25 FY26 Adjusted ROCE % 82.0% 87.2% 89.7% 68.2% 64.7% 70.8% 80.5% 54.4% FY23 FY24 FY25 FY26 Cash Conversion (%) OCF % FCF % ₹22,863 ₹21,678 ₹10,433 ₹1,962 2.23 1.90 0.71 0.09 - 0.50 1.00 1.50 2.00 2.50 ₹0 ₹5,000 ₹10,000 ₹15,000 ₹20,000 ₹25,000 FY23 FY24 FY25 FY26 Net Debt Net Debt (in ₹ Million) Net Debt to Adjusted EBITDA Particulars Q4 FY26 Q3 FY26 Q4 FY25 YoY% QoQ% FY26 FY25 YoY% Revenue from Operation 20,243 19,712 15,685 29.1% 2.7% 71,929 55,699 29.1% Employee benefits expense* 12,580 12,211 9,429 44,506 33,283 Other expenses^ 2,627 2,376 2,079 9,223 7,731 Adjusted EBITDA** 5,036 5,125 4,176 20.6% -1.7% 18,200 14,685 23.9% Adjusted EBITDA % 24.9% 26.0% 26.6% 25.3% 26.4% Adjustments: M&A Earnouts 150 42 207 475 571 SAR (stock appreciation right) – Non Cash 39 -61 104 122 1,134 Other Income^^ 82 84 101 281 386 Forex Gain / (Loss) 166 -33 -135 698 177 Reported EBITDA 5,094 5,195 3,832 33.0% -1.9% 18,583 13,542 37.2% Finance costs 221 247 298 992 1,271 Depreciation and amortisation 1,242 1,235 1,143 4,874 4,669 Profit before Exceptional Items 3,632 3,713 2,390 52.0% -2.2% 12,717 7,602 67.3% Statutory impact of new labor code in India 328 328 Profit Before Tax 3,632 3,385 2,390 52.0% 7.3% 12,389 7,602 63.0% Tax Expenses 1,055 709 564 3,141 2,211 Reported Profit After Tax 2,577 2,677 1,826 41.2% -3.7% 9,248 5,391 71.5% EPS 0.56 0.57 0.39 41.2% -3.7% 1.98 1.17 69.2% Adjusted PAT 3,069 3,229 2,398 28.0% -5.0% 11,306 8,107 39.5% Adjusted PAT % 15.2% 16.4% 15.3% 15.7% 14.6% Adjusted EPS(₹) 0.66 0.69 0.51 28.0% -5.0% 2.42 1.76 37.6% Q4 FY26 Consolidated Profit and Loss Amt in ₹ M *Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). ► Prescribes uniform definition of wages based on which employee benefits like gratuity, leave encashment & statutory bonus are computed. ► Past service costs of INR 294.7M towards Gratuity and INR 33.5M towards Compensated absence reported as exceptional items in Q3. ► Ongoing impact on overall Margins is likely to be 0.2% of Revenues. New Labor Code in India effective 21Nov 2025: Adjustments on EBITDA and PAT 16 Adj EBITDA Bridge: Q4 FY26 (₹M) Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible) Adj C - Amortization of intangible assets (net of tax) that got created due to carveout of healthcare business from HGS Adj D- Exceptional items for Q3 FY26 represents adjustment for labour codes (net of deferred tax) on account of increase in gratuity liability arising out of past service cost and increase in leave liability Adj PAT Bridge: Q4 FY26 (₹M) Adj EBITDA Bridge: FY26 (₹M) Adj PAT Bridge: FY26 (₹M) Reported EBITDA Adj A Adj B Other income/ FX gain Adjusted EBITDA Reported EBITDA Adj A Adj B Other income/ FX gain Adjusted EBITDA Reported PAT Adj A Adj B Adj C Adjusted PAT ₹150 ₹39 -₹248 ₹5,094 ₹5,036 Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA ₹18,583 ₹475 ₹122 -₹980 ₹18,200 Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA ₹2,577 ₹108 ₹39 ₹345 ₹3,069 ₹9,248 ₹344 ₹122 ₹1,346 ₹246 ₹11,306 Reported PAT Adj A Adj B Adj C Adj D Adjusted PAT Go Forward Positions Particulars FY25 FY26 FY27 FY28 FY29 FY30 Closing Debt position 8,020 5,670 - - - - Debt Repayment 2,490 2,350 5,670 - - - Interest Payment 751 543 287 - - - Share based Payment awards 1,134 122 138 72 37 - Earnouts Cost - DCI / Birch/ BroadPath 571 475 6 - - - Intangibles Amortisation (A) 1,400 1,462 1,562 1,562 1,562 1,562 Intangibles Amortisation (B) 188 392 408 392 312 265 Debt to be fully repaid by FY27. Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33 Amt in ₹ M Balance Sheet – 31st March 26 Particulars Mar 26 Mar 25 Property, plant and equipment 4,624 3,699 Right-of-use assets 4,868 5,521 Goodwill 64,051 60,390 Other intangible assets 20,407 20,362 Trade receivables and unbilled 18,390 12,668 Cash and cash equivalents (including investments) 9,038 3,438 Deferred tax assets (net) 1,514 1,337 Other Assets 3,114 3,091 Total Assets 126,011 110,507 Equity 96,591 83,361 Borrowings 5,776 8,170 Lease liabilities 5,330 5,850 Trade payables 2,217 2,136 Deferred tax liabilities (net) 4,211 4,279 Other Liabilities 11,887 6,712 Total Liabilities 126,011 110,507 Amt in ₹ M Cash Flow – FY26 Particulars FY26 FY25 Profit before tax for the period/ year 12,389 7,602 Adjustment for Non-Operating and Non-Cash items 5,271 6,982 Adjustment for working capital (1,895) (710) Income taxes paid (net of refunds) (3,735) (1,734) Net cash flows generated from operating activities (A) - OCF 12,030 12,141 Addition to Fixed Assets (1,922) (1,244) Free Cash flow (FCF) 10,108 10,896 Cash paid for M&A - (4,825) Pending Purchase consideration paid for healthcare business carveout - (3,756) Investment in Mutual fund and Fixed Deposit (5,370) - Others 185 184 Net cash flows (used in) investing activities (B) (7,107) (9,642) Capital infused by promoter - 3,708 Share Issue expense (paid)/ reimbursed - 72 Repayment of Promoter borrowings (include Interest) (2,937) (4,567) Repayment of lease liabilities (include Interest) (1,843) (1,774) Dividend paid (234) - Net cash flows (used in) financing activities (C) (5,014) (2,561) Net increase/ (decrease) in cash and cash equivalents (A+B+C) (91) (62) Cash and cash equivalents at the beginning of the year/period 3,438 3,441 Effect of movement in exchange rates on cash and cash equivalents 233 58 Cash and cash equivalents at the end of the year/ period 3,579 3,438 Net cash flows generated from operating activities % (OCF on Reported EBITDA) 64.7% 89.7% Free Cash flow % (FCF on Reported EBITDA) 54.4% 80.5% Amt in ₹ M Thank you.